Thrombophilia due to factor V and factor II mutations and formation of a dural arteriovenous fistula: Case report and review of a rare entity

Skull Base

Volumn 18, Issue 2, 2008, Pages 135-144

  Safavi Abbasi, Sam ^a,b   Di Rocco, Federico ^a   Nakaji, Peter ^b   Feigl, Guenther C ^a   Gharabaghi, Alireza ^a   Samii, Madjid ^a   Valavanis, Anton ^a   Samii, Amir ^a  

^a INTERNATIONAL NEUROSCIENCE INSTITUTE   (Germany)

^b BARROW NEUROLOGICAL INSTITUTE   (United States)

Author keywords

Anticoagulation; Arteriovenous malformation; Factor V leiden mutation; G20210A mutation; Hypercoagulable state

Indexed keywords

ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 5; HEPARIN; PROTHROMBIN; WARFARIN;

ADULT; ARTERIOVENOUS FISTULA; ARTICLE; BRAIN ANGIOGRAPHY; BRAIN HEMORRHAGE; CASE REPORT; CEREBRAL SINUS THROMBOSIS; COMPUTER ASSISTED TOMOGRAPHY; CRANIOTOMY; DURAL ARTERIOVENOUS FISTULA; FOLLOW UP; GENE MUTATION; HEMATOMA; HETEROZYGOSITY; HUMAN; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; OCCLUSIVE CEREBROVASCULAR DISEASE; PRIORITY JOURNAL; RECANALIZATION; RECURRENT DISEASE; RISK REDUCTION; THROMBOPHILIA;

EID: 43849085333     PISSN: 15315010     EISSN: 15320065     Source Type: Journal    
DOI: 10.1055/s-2007-1003926     Document Type: Article

References (42)

1. Lanzino G, Jensen ME, Kongable GL, Kassell NF. Angiographic characteristics of dural arteriovenous malformations that present with intracranial hemorrhage. Acta Neurochir (Wien) 1994;129:140-145
2. Halbach VV. Embolization of dural arteriovenous malformations. In: Valavanis A, ed. Interventional Neuroradiology. Berlin/New York: Springer-Verlag; 1993:35-54
3. Gordon IJ, Shah BL, Hardman DR, Chameides L. Giant dural supratentorial arteriovenous malformation. AJR Am J Roentgenol 1977;129:734-736
4. Newton TH, Cronqvist S. Involvement of dural arteries in intracranial arteriovenous malformations. Radiology 1969; 93:1071-1078
5. Awad IA, Little JR, Akarawi WP, Ahl J. Intracranial dural arteriovenous malformations: factors predisposing to an aggressive neurological course. J Neurosurg 1990;72:839-850
6. Herman JM, Spetzler RF, Bederson JB, Kurbat JM, Zabramski JM. Genesis of a dural arteriovenous malformation in a rat model. J Neurosurg 1995;83:539-545
7. Houser OW, Campbell JK, Campbell RJ, Sundt TM Jr. Arteriovenous malformation affecting the transverse dural venous sinus: an acquired lesion. Mayo Clin Proc 1979; 54:651-661
8. Mullan S. Reflections upon the nature and management of intracranial and intraspinal vascular malformations and fistulae. J Neurosurg 1994;80:606-616
9. Ozawa T, Miyasaka Y, Tanaka R, Kurata A, Fujii K. Dural-pial arteriovenous malformation after sinus thrombosis. Stroke 1998;29:1721-1724
10. Deschiens MA, Conard J, Horellou MH, et al. Coagulation studies, factor V Leiden, and anticardiolipin antibodies in 40 cases of cerebral venous thrombosis. Stroke 1996;27:1724-1730
11. Kimber J. Cerebral venous sinus thrombosis. QJM 2002; 95:137-142
12. Kraus JA, Stuper BK, Nahser HC, Klockgether T, Berlit P. Significantly increased prevalence of factor V Leiden in patients with dural arteriovenous fistulas. J Neurol 2000; 247:521-523
13. Soleau SW, Schmidt R, Stevens S, Osborn A, MacDonald JD. Extensive experience with dural sinus thrombosis. Neurosurgery 2003;52:534-544
14. Svensson PJ, Dahlback B. Resistance to activated protein C as a basis for venous thrombosis. N Engl J Med 1994; 330:517-522
15. Dahlback B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci U S A 1993;90:1004-1008
16. Koster T, Rosendaal FR, de Ronde H, Briet E, Vandenbroucke JP, Bertina RM. Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study. Lancet 1993;342:1503-1506
17. Price DT, Ridker PM, Factor V. Leiden mutation and the risks for thromboembolic disease: a clinical perspective. Ann Intern Med 1997;127:895-903
18. Rosendaal FR, Koster T, Vandenbroucke JP, Reitsma PH. High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance). Blood 1995;85: 1504-1508
19. Sun X, Evatt B, Griffin JH. Blood coagulation factor Va abnormality associated with resistance to activated protein C in venous thrombophilia. Blood 1994;83:3120-3125
20. Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996;88:3698-3703
21. Ridker PM, Hennekens CH, Miletich JP. G20210A mutation in prothrombin gene and risk of myocardial infarction, stroke, and venous thrombosis in a large cohort of US men. Circulation 1999;99:999-1004
22. De Stefano V, Martinelli I, Mannucci PM, et al. The risk of recurrent deep venous thrombosis among heterozygous carriers of both factor V Leiden and the G20210A prothrombin mutation. N Engl J Med 1999;341:801-806
23. Zoller B, Garcia DF, Hillarp A, Dahlback B. Thrombophilia as a multigenic disease. Haematologica 1999;84:59-70
24. Kraus JA, Stuper BK, Berlit P. Association of resistance to activated protein C and dural arteriovenous fistulas. J Neurol 1998;245:731-733
25. Gerlach R, Yahya H, Rohde S, et al. Increased incidence of thrombophilic abnormalities in patients with cranial dural arteriovenous fistulae. Neurol Res 2003;25:745-748
26. Cognard C, Gobin YP, Pierot L, et al. Cerebral dural arteriovenous fistulas: clinical and angiographic correlation with a revised classification of venous drainage. Radiology 1995;194:671-680
27. Satomi J, van Dijk JM, Terbrugge KG, Willinsky RA, Wallace MC. Benign cranial dural arteriovenous fistulas: outcome of conservative management based on the natural history of the lesion. J Neurosurg 2002;97:767-770
28. Hamada Y, Goto K, Inoue T, et al. Histopathological aspects of dural arteriovenous fistulas in the transversesigmoid sinus region in nine patients. Neurosurgery 1997; 40:452-456
29. Terada T, Higashida RT, Halbach VV, et al. Development of acquired arteriovenous fistulas in rats due to venous hypertension. J Neurosurg 1994;80:884-889
30. Lawton MT, Jacobowitz R, Spetzler RF. Redefined role of angiogenesis in the pathogenesis of dural arteriovenous malformations. J Neurosurg 1997;87:267-274
31. Zhu Y, Lawton MT, Du R, et al. Expression of hypoxia-inducible factor-1 and vascular endothelial growth factor in response to venous hypertension. Neurosurgezy 2006;59: 687-696
32. Einhaupl KM, Villringer A, Meister W, et al. Heparin treatment in sinus venous thrombosis. Lancet 1991;338: 597-600
33. Bertina RM, Koeleman BP, Koster T, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994;369:64-67
34. Dahlback B. New molecular insights into the genetics of thrombophilia: resistance to activated protein C caused by Arg506 to Gln mutation in factor V as a pathogenic risk factor for venous thrombosis. Thromb Haemost 1995; 74:139-148
35. Simioni P, Prandoni P, Lensing AW, et al. Risk for subsequent venous thromboembolic complications in carriers of the prothrombin or the factor V gene mutation with a first episode of deep-vein thrombosis. Blood 2000; 96:3329-3333
36. Rees DC, Chapman NH, Webster MT, Guerreiro JF, Rochette J, Clegg JB. Born to clot: the European burden. Br J Haematol 1999;105:564-566
37. Rodeghiero F, Tosetto, A. Activated protein C resistance and factor V Leiden mutation are independent risk factors for venous thromboembolism. Ann Intern Med 1999;130: 643-650
38. Margaglione M, Brancaccio V, Giuliani N, et al. Increased risk for venous thrombosis in carriers of the prothrombin G→A20210 gene variant. Ann Intern Med 1998;129:89-93
39. Simioni P, Prandoni P, Lensing AW, et al. The risk of recurrent venous thromboembolism in patients with an Arg506-Gln mutation in the gene for factor V (factor V Leiden). N Engl J Med 1997;336:399-403
40. Martinelli I, Sacchi E, Landi G, Taioli E, Duca F, Mannucci PM. High risk of cerebral-vein thrombosis in carriers of a prothrombin-gene mutation and in users of oral contraceptives. N Engl J Med 1998;338:1793-1797
41. De Stefano V, Martinelli I, Mannucci PM, et al. The risk of recurrent venous thromboembolism among heterozygous carriers of the G20210A prothrombin gene mutation. Br J Haematol 2001;113:630-635
42. Bauer KA. Role of thrombophilia in deciding on the duration of anticoagulation. Semin Thromb Hemost 2004; 30:633-637